Source comparison
CJC 1295 No DAC Versus CJC 1295 With DAC: Research Application Differences
The table below clarifies which analog fits which experimental model—choosing the wrong version is the most common protocol error we see from research teams new to GHRH analogs. Plasma Half-Life 30 minutes or less ~8 days No-DAC requires multiple daily doses;
This comparison does not assign a generated winner or score.
- The table below clarifies which analog fits which experimental model—choosing the wrong version is the most common protocol error we see from research teams new to GHRH analogs.
- Plasma Half-Life
- 30 minutes or less
- ~8 days
- No-DAC requires multiple daily doses; with-DAC requires weekly dosing
- No-DAC preserves pulsatility; with-DAC sustains non-physiological elevation
- GH Secretion Pattern
- Pulsatile (discrete peaks)
- Sustained (continuous elevation)
- No-DAC mimics endogenous rhythm; with-DAC overrides it
- Use no-DAC for studies requiring natural GH dynamics
- Dosing Frequency
- 2–3× daily (typically upon waking, pre-workout, before sleep)
- 1–2× weekly
- No-DAC aligns with natural GH pulse timing
- No-DAC demands stricter timing compliance
- Synergy With GHRPs
- High—amplifies pulsatile peaks 3–5×
- Minimal—sustained GH blunts GHRP response
- Combination protocols require no-DAC for synergy
- With-DAC eliminates the mechanistic rationale for GHRP co-administration
- Receptor Downregulation Risk
- Low—pulsatile exposure allows receptor recovery
- Moderate to high—continuous receptor occupancy reduces sensitivity over time
- Long-term with-DAC studies may show diminishing GH response after 8–12 weeks
- No-DAC better suited for chronic studies beyond three months
- IGF-1 Elevation Profile
- Moderate, fluctuating (follows GH pulses)
- High, sustained (chronic GH stimulation)
- No-DAC produces physiological IGF-1 variability; with-DAC creates supraphysiological steady-state
- Choose based on whether your model studies acute versus chronic IGF-1 signaling